Disclaimer

Important information

The information contained in this section of Oasmia Pharmaceutical AB’s (publ) (“Oasmia”) website is not intended for, and must not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or physically present in Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa, the United States or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction, and does not constitute an offer to sell or the solicitation of an offer to buy or acquire, any shares or other securities of Oasmia in Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa, the United States, or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction.

No subscription rights, paid subscription shares (Sw. betalda tecknade aktier) or new shares in Oasmia (“Securities”) have been, or will, be, registered under the United States Securities Act of 1933, as amended (the “Securities Act”) or the securities legislation of any state or other jurisdiction of the United States and thus the Securities may not be offered, subscribed for, exercised, pledged, sold, resold, granted, delivered or otherwise transferred, directly or indirectly, within the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities legislation in any state or other jurisdiction of the United States. The Securities have not been approved or disapproved by the U.S. Securities and Exchange Commission (SEC), any state regulatory authority in the United States or any other U.S. regulatory authority nor have any of the foregoing authorities passed upon or endorsed the merits of the offering or the accuracy or adequacy of the prospectus. Any representation to the contrary is a criminal offense in the United States.

No public offering of Securities is made to any countries within the European Economic Area (“EEA”) other than Sweden. In other member states of the EEA, Sweden included, an offer of Securities can only be made in accordance with exeptions in the EU prospectus regulation (Regulation (EU) 2017/1129) and every relevant implementation measure.

Access to the information and documents contained on the following websites may be illegal in certain jurisdictions, and only certain categories of persons may be authorized to access such information and documents. All persons residing outside of Sweden who wish to have access to the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. No such registration or approval has been obtained outside Sweden. Oasmia assumes no responsibility if there is a violation of applicable law and regulations by any person.

Select the country in which you reside:
Please enter your country of residence: